CellAegis Announces Completion of Patient Enrollment in First North American Study for Innovative Heart Attack Therapy Using autoRIC®
TORONTO, Sept. 11, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced completion of patient enrollment in a large scale, investigator sponsored study (“FIRST”) to evaluate the clinical and economic benefits of Remote Ischemic Conditioning (“RIC”) therapy in the treatment of patients presenting with ST-segment-elevation myocardial infarction (“STEMI”) heart attacks, as delivered by CellAegis’ autoRIC® device.
Sponsored by William Osler Health System, FIRST will examine clinical outcomes and costs of treatment for 1,800 STEMI heart attack patients receiving RIC, as delivered by CellAegis’ autoRIC® device (http://cellaegis.com/products/), therapy as compared to standard treatment at the first point of medical contact (in an ambulance or at the hospital). Results of the study are expected to be published early in 2019.
“We are extremely excited to complete enrollment in this, the first ever North American study designed to explore the use of RIC treatment prior to coronary intervention to reduce the heart muscle damage from a STEMI heart attack,” said Dr. Sheldon Cheskes, Medical Director of the Sunnybrook Centre for Prehospital Medicine, and principal investigator of FIRST. “This study has the potential to truly impact outcomes through the use of a simple, inexpensive technique that can be applied either in the emergency department or prehospital [ambulance] care field.”
“The FIRST study exemplifies how innovative healthcare can be evaluated in real-world settings using existing infrastructure across a healthcare region,” said Dr. Ronald Heslegrave, Chief of Research and study sponsor at William Osler Health System. “Osler’s catchment area has very high cardiovascular risks compared to other parts of Ontario, and we are excited that the FIRST study gives us a chance to quantify the benefits of this cardioprotective therapy in our population. If we obtain the expected result, such as decreased readmissions to hospitals, the autoRIC® device could be put into ambulances and emergency rooms across Ontario, which could have a huge impact on the community we serve as well as communities throughout the province.”
“There are approximately 160,000 Canadians who annually receive a diagnosis of ischemic heart disease and about 63,000 who have a first heart attack. There are an estimated one million STEMI heart attacks annually in North America and Europe that may benefit from RIC therapy using our autoRIC® device,” commented Rocky Ganske, Chief Executive Officer, CellAegis.
FIRST is supported by the Ontario Centres of Excellence in partnership with Shared Services West. Partner ambulance services include Peel Paramedic and Halton Paramedic Services, with partner cardiac hospitals Trillium Health Partners, and Brampton Civic Hospital. Research support is provided by the Institute of Clinical and Evaluative Sciences at Sunnybrook Hospital.
“CellAegis wants to recognize and thank the many healthcare professionals who made FIRST possible,” continued Mr. Ganske. “This real-world clinical implementation could not have been done without the devotion and dedication of paramedic services, and the many emergency and cath lab doctors and nurses of Peel and Halton Region who applied our autoRIC® device to administer the RIC therapy. CellAegis looks forward to repeating a full clinical implementation in all health systems across Ontario and Canada upon the company’s anticipation of strong supporting economics data from this study.”
RIC is a noninvasive therapy that utilizes four cycles of limb occlusion and reperfusion to protect the heart and other tissue against ischemia-reperfusion injury. RIC is a promising adjunctive treatment to stenting in the prevention of ischemic-reperfusion injury and minimization of post-infarct heart failure in ST-elevation myocardial infarction (“STEMI”) patients. Previous proof-of-concept clinical studies with RIC have demonstrated improvements in markers of injury, such as increased myocardial salvage and reduced infarct size as well as reduction of contrast-induced acute kidney injury, in various clinical scenarios such as heart attacks and elective cardiac procedures.
About CellAegis Devices
CellAegis Devices (http://cellaegis.com/about-us/), headquartered in Toronto, Canada, is the world leader in automated remote ischemic conditioning. The company has patented and developed the non-invasive autoRIC® device, which delivers RIC therapy to patients with acute and chronic cardiovascular conditions. The autoRIC® device has CE Mark and Health Canada approvals for treatment during heart attacks, cardiothoracic or surgical procedures, and is currently limited to investigational use in the United States. Investigator sponsored clinical research studies for chronic conditions such as heart failure and stroke are also underway. The autoRIC® device was developed from the clinical work of clinicians and researchers at Toronto’s world-renowned Hospital for Sick Children.
This press release may contain forward-looking statements identified by words such as “expects”, “anticipates”, “will” and similar expressions, which reflect CellAegis’ current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company’s actual events to differ materially from those projected herein. The forward-looking statements are made as of the date of this press release and CellAegis does not undertake and is not obligated to publicly update such forward looking statements to reflect new information, subsequent events or otherwise, except as required by law.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Avis Budget Group Wins Multiple Awards in the Middle East26.4.2019 12:43:00 CEST | Pressemelding
LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Avis Budget Group has been awarded multiple accolades at the 2019 World Travel Awards, for its car rental brands Avis and Budget, across the Middle East, it was announced at an awards ceremony in Abu Dhabi last night. The 26th annual World Travel Awards is globally recognized as a highly prestigious honours programme in global travel and tourism. The awards are voted for by travel and tourism professionals and consumers worldwide, and this honour recognises the brands’ commitment to excellence, with an ultimate industry accolade. The awards won by these licensee markets within Avis Budget Group include: Middle East's Leading Business Car Rental Company 2019: Avis Bahrain's Leading Car Rental Company 2019: Avis Iraq's Leading Car Rental Company 2019: Avis Kuwait's Leading Car Rental Company 2019: Avis Lebanon's Leading Car Rental Company 2019: Avis Oman's Leading Car Rental Company 2019: Avis United Arab Emirates’ Leading Car Rental Company 201
Mohawk Industries Reports Q1 Results25.4.2019 22:15:00 CEST | Pressemelding
CALHOUN, Ga., April 25, 2019 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) today announced 2019 first quarter net earnings of $122 million and diluted earnings per share (EPS) of $1.67. Adjusted net earnings were $154 million, and EPS was $2.13, excluding restructuring, acquisition and other charges. Net sales for the first quarter of 2019 were $2.44 billion, up 1% in the quarter and 6% on a constant currency and days basis. For the first quarter of 2018, net sales were $2.41 billion, net earnings were $209 million and EPS was $2.78, adjusted net earnings were $225 million, and EPS was $3.01, excluding restructuring, acquisition and other charges. Commenting on Mohawk Industries’ first quarter performance, Jeffrey S. Lorberbaum, Chairman and CEO, stated, “In the first quarter, we delivered results in-line with the high end of our expectations despite economies weakening in most regions and a stronger U.S. dollar, reducing our translated results. While U.S. housing markets beg
Oxford Immunotec Schedules First Quarter 2019 Earnings Release and Conference Call for May 9, 201925.4.2019 22:05:00 CEST | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2019 financial results before the open of the market on Thursday, May 9, 2019. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 6687808, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on th
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 201925.4.2019 22:05:00 CEST | Pressemelding
GAITHERSBURG, Md., April 25, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, May 2, 2019. Conference call details are as follows: Date: May 2, 2019 Time: 4:30 p.m. U.S. Eastern Time (ET) Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International) Passcode: 5394082 Webcast: www.novavax.com, “Investors”/ “Events” Conference call and webcast replay: Dates: Starting at 7:30 p.m. ET, May 2, 2019 until 7:30 p.m. ET May 9, 2019 Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International) Passcode: 5394082 Webcast: www.novavax.com, “Investors”/ “Events”, until August 2, 2019 About Novavax Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its tw
BGRS Acquired by Relo Group, Inc.25.4.2019 17:55:00 CEST | Pressemelding
CHICAGO and TOKYO, April 25, 2019 (GLOBE NEWSWIRE) -- Relo Group, Inc. (“Relo Group”) and BGRS (“BGRS” or the “Company”) announced today that they have entered into a definitive agreement under which an affiliate of Relo Group will acquire BGRS, a leading global talent mobility management firm from Brookfield Business Partners. Leading the global mobility industry with innovative outsourcing and fully integrated solutions, BGRS provides a full spectrum of talent mobility and advisory services to Global Fortune 500 companies. Supported by a team of over 1,300 globally, BGRS manages over 60,000 employee relocations annually with locations throughout Asia, the Americas and EMEA. BGRS Chief Executive Officer, Traci Morris, and the management team will remain in place and work with Relo Group to advance the Company into its next phase. “BGRS has developed into a world class talent mobility management firm by always putting the interests of our clients first, constantly innovating and search
Ascom adds ‘talk before walk’ wireless speech function to new release of Ascom teleCARE IP25.4.2019 14:00:00 CEST | Pressemelding
New feature helps reduce caregivers’ walking time; enables more streamlined workflows in elderly care facilities BAAR, Switzerland, April 25, 2019 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), a global solutions provider focused on healthcare ICT and mobile workflow solutions, has added wireless speech functionality to its latest version of the Ascom teleCARE IP emergency call system. The new feature promises to help reduce the time spent by staff walking to investigate calls from residents in continuing and elderly care facilities. Ascom teleCARE IP has always had hardwired speech functionality. But by making it wireless, residents can simply use their normal mobile phones to communicate directly with caregivers via Ascom teleCARE IP. Caregivers can communicate with residents while on the go, and can deal with residents’ calls before walking to investigate. The newly released (Ascom teleCARE IP 12) is available globally. The latest version also features several technical enhancements inclu